

Claims 1-3, 5-9, 11, 13-14, 16-18, 21, 23-27 and 29 of the '284 patent are unpatentable as Obvious Over *Bernasconi* in View of *INOMAX label*, *Loh*, and *Goyal*.

U.S. Pat. No. 8,293,284	<i>Bernasconi</i> , <i>INOMAX label</i> , <i>Loh</i> , and <i>Goyal</i>
CLAIM 1	
A method of reducing the risk of occurrence of pulmonary edema associated with a medical treatment comprising inhalation of 20 ppm nitric oxide gas, said method comprising:	See Sections (a)-(c) of Claim 1 below.
(a) performing echocardiography to identify a term or near-term neonate patient in need of 20 ppm inhaled nitric oxide treatment for pulmonary hypertension, wherein the patient is not dependent on right-to-left shunting of blood;	<p><i>Bernasconi</i> teaches that echocardiography is essential to identify and treat pediatric patients with conditions, such as pulmonary hypertension, that may be treated with inhaled nitric oxide (“iNO”).</p> <p>PPHN is a syndrome associated with diverse neonatal cardiopulmonary disorders, which are characterised by a high pulmonary vascular resistance with right to left shunt of deoxygenated blood across the ductus arteriosus and/or the foramen ovale. The role of echocardiography to confirm the diagnosis and conduct therapy is therefore essential.</p> <p>Ex. 1004 at 8.</p> <p><i>Bernasconi</i> further teaches treating neonates with persistent pulmonary hypertension of the newborn (“PPHN”) with iNO and that the FDA recommended dose for neonatal hypoxic respiratory failure is 20 ppm iNO.</p> <p>The appropriate dose of iNO to assess pulmonary vascular resistance or treat pulmonary hypertension is not completely defined. Dose response studies have been performed in persistent pulmonary hypertension of the newborn (PPHN) and ARDS⁴¹⁻⁴⁶ and in congenital heart disease.⁴⁷⁻⁴⁸ Inhaled NO doses required to treat pulmonary hypertension are higher than those required for improvement of ventilation</p> <p>The recommended dose by the FDA for the treatment of neonatal hypoxic respiratory failure is 20 ppm.</p> <p>Ex. 1004 at 3.</p> <p><i>INOMAX label</i> teaches that echocardiography can be used to identify patients with pulmonary hypertension that may be</p>

U.S. Pat. No. 8,293,284	<i>Bernasconi, INOMAX label, Loh, and Goyal</i>
	<p>treated with iNO.</p> <p>INOMax, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.</p> <p>Ex. 1014 at 4.</p> <p><i>INOMAX label</i> further teaches the FDA recommended dose for iNO treatment is 20 ppm.</p> <p>The recommended dose of INOMax is 20 ppm. Treatment should be maintained up to 14 days or until the underlying oxygen desaturation has resolved and the neonate is ready to be weaned from INOMax therapy.</p> <p>Ex. 1014 at 6.</p> <p><i>INOMAX label</i> further teaches that iNO should not be used in patients dependent on right-to-left shunting of blood.</p> <p>CONTRAINDICATIONS</p> <p>INOMax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood.</p> <p>Ex. 1014 at 4.</p>
<p>(b) determining that the patient identified in (a) has a pulmonary capillary wedge pressure greater than or equal to 20 mm Hg and thus has left ventricular dysfunction, so is at particular risk of pulmonary edema upon treatment with inhaled nitric oxide; and</p>	<p><i>Bernasconi</i> teaches that there are negative effects of iNO in patients with left ventricular dysfunction (“LVD”) including a risk of causing pulmonary edema.</p> <p>There are several reports of the negative effects of inhaled NO in patients with left ventricular dysfunction and elevated pulmonary vascular resistance.¹⁰³⁻¹⁰⁸ Inhaled NO produces selective pulmonary vasodilatation. However, in patients with elevated left atrial pressure due to left ventricular dysfunction, a decrease in pulmonary vascular resistance (induced by iNO) will lead to an increase in pulmonary venous return and hence to an increase in left atrial and left ventricular filling pressures; this may not be tolerated by a failing left ventricle working on the flat portion of the Frank-Starling curve.¹⁰⁸ This effect may lead to rapid left heart failure and pulmonary oedema, most marked if the right ventricular pressure is suprasystemic and the left cavity small.¹⁰³</p> <p>Ex. 1004 at 8.</p> <p><i>Loh</i> teaches measuring a baseline wedge pressure prior to administering iNO. (Wedge pressure may also be called pulmonary capillary wedge pressure (“PCWP”), pulmonary arterial wedge pressure (“PAWP”), or merely “wedge.” All the terms refer to the same concept). <i>Loh</i> further teaches that patients with LVD have a baseline wedge pressure that is greater than 20 mm Hg.</p>

studied the hemodynamic effects of a 10-minute inhalation of NO (80 ppm) in 19 patients with moderate to severe heart failure secondary to LV dysfunction from idiopathic or ischemic dilated cardiomyopathy.

Ex. 1006 at 2780.

To establish baseline conditions, patients inhaled room air (FIO₂, 21%; N₂, 79%) via the closed face mask system for 10 minutes before the baseline hemodynamic measurements. Patients then inhaled NO at 80 ppm (FIO₂, 21%; N₂, 79%)

Ex. 1006 at 2781.

TABLE 1. Hemodynamic Effects of Inhaled NO in Patients With Congestive Heart Failure (n=19)

	Room Air	NO	P
HR, bpm	90±3	93±3	NS
MAP, mm Hg	79±3	81±3	NS
SVR, dyne · s · cm ⁻⁵	1102±104	1041±97	NS
PA, mm Hg	35±4	37±4	NS
PAWP, mm Hg	25±3	31±4	<.001
LVEDP, mm Hg; n=10	28±4	34±5	.02
PVR, dyne · s · cm ⁻⁵	226±30	119±13	<.001
PA-PAWP, mm Hg	11±1	6±0.5	<.001
SVI, mL/m ²	26±2	24±2	.03
CI, L · min ⁻¹ · m ⁻²	2.3±0.2	2.1±0.2	.03

HR indicates heart rate; bpm, beats per minute; MAP, mean arterial pressure; SVR, systemic vascular resistance; PA, mean pulmonary artery measure; PAWP, pulmonary artery wedge pressure; LVEDP, left ventricular end-diastolic pressure; PVR, pulmonary vascular resistance; SVI, stroke volume index; and CI, cardiac index.

Ex. 1006 at Table 1.

Additionally, *Goyal* teaches measuring wedge pressure in infants.

During cardiac catheterization study, baseline heart rate, systolic, diastolic and mean systemic as well as PA pressures, right atrial pressure and pulmonary capillary wedge pressure (PCWP) were recorded for all the patients

Ex. 1007 at 209.

<p>U.S. Pat. No. 8,293,284</p>	<p><i>Bernasconi, INOMAX label, Loh, and Goyal</i></p>																						
	<p>Table 1 Patient characteristics. Data are expressed as median (range) or absolute numbers. BSA, body surface area; Hb, haemoglobin; VSD, ventricular septal defect</p> <hr/> <table border="0"> <tr> <td>Age (months)</td> <td>33 (8–54)</td> </tr> <tr> <td>M:F</td> <td>12:7</td> </tr> <tr> <td>Weight (kg)</td> <td>11 (5–17)</td> </tr> <tr> <td>Height (cm)</td> <td>89(64–115)</td> </tr> <tr> <td>BSA (m²)</td> <td>0.52 (0.29–0.75)</td> </tr> <tr> <td>Hb (gm dl⁻¹)</td> <td>11.2 (10–14)</td> </tr> <tr> <td>Type of VSD</td> <td></td> </tr> <tr> <td> Perimembranous</td> <td>15</td> </tr> <tr> <td> Muscular</td> <td>2</td> </tr> <tr> <td> Multiple muscular</td> <td>1</td> </tr> <tr> <td> Perimembranous with muscular</td> <td>1</td> </tr> </table> <hr/> <p>Ex. 1007 at Table 1.</p>	Age (months)	33 (8–54)	M:F	12:7	Weight (kg)	11 (5–17)	Height (cm)	89(64–115)	BSA (m ²)	0.52 (0.29–0.75)	Hb (gm dl ⁻¹)	11.2 (10–14)	Type of VSD		Perimembranous	15	Muscular	2	Multiple muscular	1	Perimembranous with muscular	1
Age (months)	33 (8–54)																						
M:F	12:7																						
Weight (kg)	11 (5–17)																						
Height (cm)	89(64–115)																						
BSA (m ²)	0.52 (0.29–0.75)																						
Hb (gm dl ⁻¹)	11.2 (10–14)																						
Type of VSD																							
Perimembranous	15																						
Muscular	2																						
Multiple muscular	1																						
Perimembranous with muscular	1																						
<p>(c) excluding the patient from inhaled nitric oxide treatment based on the determination that the patient has left ventricular dysfunction and so is at particular risk of pulmonary edema upon treatment with inhaled nitric oxide.</p>	<p><i>Bernasconi</i> teaches that patients with LVD treated with iNO are at risk of pulmonary edema.</p> <p>There are several reports of the negative effects of inhaled NO in patients with left ventricular dysfunction and elevated pulmonary vascular resistance.^{103–108} Inhaled NO produces selective pulmonary vasodilatation. However, in patients with elevated left atrial pressure due to left ventricular dysfunction, a decrease in pulmonary vascular resistance (induced by iNO) will lead to an increase in pulmonary venous return and hence to an increase in left atrial and left ventricular filling pressures; this may not be tolerated by a failing left ventricle working on the flat portion of the Frank-Starling curve.¹⁰⁸ This effect may lead to rapid left heart failure and pulmonary oedema, most marked if the right ventricular pressure is suprasystemic and the left cavity small.¹⁰³</p> <p>Ex. 1004 at 8.</p>																						
<p>CLAIM 2</p>																							
<p>The method of claim 1, wherein step (b) comprises performing echocardiography.</p>	<p>All the elements of the independent claim from which this claim depends are disclosed in Bernasconi, INOMAX label, Loh, and Goyal as outlined above in Claim 1.</p> <p><i>Bernasconi</i> teaches that echocardiography may be used to confirm a diagnosis and conduct therapy with iNO, as well as to exclude a condition that may contraindicate the use of iNO.</p> <p>The role of echocardiography to confirm the diagnosis and conduct therapy is therefore essential. Echocardiography also excludes structural congenital heart disease, which would contraindicate the use of iNO.</p>																						

<p>U.S. Pat. No. 8,293,284</p>	<p><i>Bernasconi, INOMAX label, Loh, and Goyal</i></p>
	<p>Ex. 1004 at 8.</p> <p><i>Bernasconi</i> further teaches that patients with LVD treated with iNO are at risk of pulmonary edema.</p> <p>There are several reports of the negative effects of inhaled NO in patients with left ventricular dysfunction and elevated pulmonary vascular resistance.¹⁰³⁻¹⁰⁸ Inhaled NO produces selective pulmonary vasodilatation. However, in patients with elevated left atrial pressure due to left ventricular dysfunction, a decrease in pulmonary vascular resistance (induced by iNO) will lead to an increase in pulmonary venous return and hence to an increase in left atrial and left ventricular filling pressures; this may not be tolerated by a failing left ventricle working on the flat portion of the Frank-Starling curve.¹⁰⁸ This effect may lead to rapid left heart failure and pulmonary oedema, most marked if the right ventricular pressure is suprasystemic and the left cavity small.¹⁰³</p> <p>Ex. 1004 at 8.</p>
<p>CLAIM 3</p>	
<p>The method of claim 1, wherein step (b) comprises measuring the patient's pulmonary capillary wedge pressure.</p>	<p>All the elements of the independent claim from which this claim depends are disclosed in Bernasconi, INOMAX label, Loh, and Goyal as outlined above in Claim 1.</p> <p><i>Loh</i> teaches measuring a baseline wedge pressure prior to administering iNO. <i>Loh</i> further teaches that patients with LVD have a baseline wedge pressure that is greater than 20 mm Hg.</p> <p>studied the hemodynamic effects of a 10-minute inhalation of NO (80 ppm) in 19 patients with moderate to severe heart failure secondary to LV dysfunction from idiopathic or ischemic dilated cardiomyopathy.</p> <p>Ex. 1006 at 2780.</p> <p>To establish baseline conditions, patients inhaled room air (FIO₂, 21%; N₂, 79%) via the closed face mask system for 10 minutes before the baseline hemodynamic measurements. Patients then inhaled NO at 80 ppm (FIO₂, 21%; N₂, 79%)</p> <p>Ex. 1006 at 2781.</p>

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.